Editas Medicine, Inc. (EDIT) stock
EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3047% above fair value
$2.38−0.13 (-4.99%)
Close on Nov 11, 2026Market cap $365.52MP/E –Yield –
Editas Medicine cash
Cash and short-term investments held at the end of each period.
Editas Medicine's cash was $190.20M at Sep 30, 2026. For fiscal 2025 it was $146.65M, down 46.4% from the year before. Over ten years it grew 0.2% a year on average. The highest annual figure on record is $503.72M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $146.65M | -46.4% |
| FY2024 | Dec 31, 2024 | $273.79M | -16.3% |
| FY2023 | Dec 31, 2023 | $326.99M | -5.0% |
| FY2022 | Dec 31, 2022 | $344.27M | -31.7% |
| FY2021 | Dec 31, 2021 | $503.72M | +24.1% |
| FY2020 | Dec 31, 2020 | $405.99M | -11.5% |
| FY2019 | Dec 31, 2019 | $458.76M | +23.8% |
| FY2018 | Dec 31, 2018 | $370.57M | +12.0% |
| FY2017 | Dec 31, 2017 | $330.76M | +76.9% |
| FY2016 | Dec 31, 2016 | $186.94M | +30.3% |
| FY2015 | Dec 31, 2015 | $143.50M | +1250.8% |
| FY2014 | Dec 31, 2014 | $10.62M | +428.0% |
| FY2013 | Dec 31, 2013 | $2.01M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $190.20M | +14.8% |
| Q2 FY2026 | Jun 30, 2026 | $211.65M | +18.6% |
| Q1 FY2026 | Mar 31, 2026 | $123.65M | -44.0% |
| Q4 FY2025 | Dec 31, 2025 | $146.65M | -46.4% |
| Q3 FY2025 | Sep 30, 2025 | $165.65M | -37.5% |
| Q2 FY2025 | Jun 30, 2025 | $178.50M | -36.0% |
| Q1 FY2025 | Mar 31, 2025 | $220.96M | -25.4% |
| Q4 FY2024 | Dec 31, 2024 | $273.79M | -16.3% |
| Q3 FY2024 | Sep 30, 2024 | $265.09M | -24.2% |
| Q2 FY2024 | Jun 30, 2024 | $279.11M | -35.4% |
| Q1 FY2024 | Mar 31, 2024 | $296.17M | -7.0% |
| Q4 FY2023 | Dec 31, 2023 | $326.99M | -5.0% |
| Q3 FY2023 | Sep 30, 2023 | $349.62M | -17.4% |
| Q2 FY2023 | Jun 30, 2023 | $431.97M | -5.4% |
| Q1 FY2023 | Mar 31, 2023 | $318.44M | -35.3% |
| Q4 FY2022 | Dec 31, 2022 | $344.27M | -31.7% |
| Q3 FY2022 | Sep 30, 2022 | $423.49M | -24.6% |
| Q2 FY2022 | Jun 30, 2022 | $456.44M | -25.7% |
| Q1 FY2022 | Mar 31, 2022 | $492.24M | -21.8% |
| Q4 FY2021 | Dec 31, 2021 | $503.72M | +24.1% |
| Q3 FY2021 | Sep 30, 2021 | $561.72M | +12.5% |
| Q2 FY2021 | Jun 30, 2021 | $614.43M | +2.0% |
| Q1 FY2021 | Mar 31, 2021 | $629.21M | +50.8% |
| Q4 FY2020 | Dec 31, 2020 | $405.99M | -11.5% |
| Q3 FY2020 | Sep 30, 2020 | $499.18M | +49.4% |
| Q2 FY2020 | Jun 30, 2020 | $602.60M | +88.6% |
| Q1 FY2020 | Mar 31, 2020 | $417.37M | +21.4% |
| Q4 FY2019 | Dec 31, 2019 | $458.76M | +23.8% |
| Q3 FY2019 | Sep 30, 2019 | $334.24M | -1.4% |
| Q2 FY2019 | Jun 30, 2019 | $319.55M | -7.6% |
| Q1 FY2019 | Mar 31, 2019 | $343.68M | -4.6% |
| Q4 FY2018 | Dec 31, 2018 | $370.57M | +12.0% |
| Q3 FY2018 | Sep 30, 2018 | $339.11M | +14.7% |
| Q2 FY2018 | Jun 30, 2018 | $345.70M | +6.4% |
| Q1 FY2018 | Mar 31, 2018 | $360.44M | +2.5% |
| Q4 FY2017 | Dec 31, 2017 | $330.76M | +76.9% |
| Q3 FY2017 | Sep 30, 2017 | $295.69M | – |
| Q2 FY2017 | Jun 30, 2017 | $324.80M | – |
| Q1 FY2017 | Mar 31, 2017 | $351.55M | – |
| Q4 FY2016 | Dec 31, 2016 | $186.94M | – |
See a number that looks wrong?